At the news
? NEUTRALIMPACT 2/10 6-K filed Sep 15, 2026 at 10:01 ET
AstraZeneca's Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares at £121.21 per share on 14 September 2026, a routine insider buy of approximately £303,000. This is a small, non-material open-market purchase by a non-executive director, representing a modest alignment signal but negligible relative to a $254B market cap. The filing is routine and carries no actionable trading signal.
- Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares on 14 September 2026.
- Purchase price was £121.213296 per share, total value approximately £303,033.
- Transaction was an open-market purchase on the London Stock Exchange (LON).
- No other material financial or operational information was disclosed in this filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access